Genfleet-B (02595) announced that its oral pan-RAS inhibitor GFH276 has entered an Ib/II multicenter, open-label combination therapy study, which will be conducted across dozens of clinical sites in China and Australia. The first overseas enrolled patient was recently dosed at Monash Health in Australia, while the first Chinese enrolled patient was dosed in the third quarter of this year at Fudan University Shanghai Cancer Center.
The study aims to evaluate the efficacy and safety of multiple combination therapies for RAS-mutant pancreatic cancer and advanced solid tumors. The Phase II stage will include three first-line pancreatic cancer treatment cohorts: GFH276 combined with cetuximab (EGFR monoclonal antibody), GFH276 combined with AG (standard chemotherapy regimen), and GFH276 combined with mFOLFIRINOX (standard chemotherapy regimen).
The Phase I monotherapy trial of GFH276 for previously treated solid tumors completed first patient dosing in September 2025, placing its clinical development progress in the first tier of domestic pan-RAS inhibitors.
According to the Late-Breaking Abstract (LBA) presented at this year's ESMO Annual Meeting, as of the data cutoff date in the GFH276 monotherapy Phase Ia trial, 72.6% of patients with pancreatic ductal adenocarcinoma (PDAC) received GFH276 as third-line or later treatment, with no dose-limiting toxicities observed at the 40-160 mg QD dose level (patients did not receive prophylactic medication). Among 61 evaluable PDAC patients (40-160 mg QD), the overall objective response rate (ORR) was 41.1%, and the ORR for patients who had not previously received RAS-targeted therapy was 43.1%.
According to multi-tumor animal study data presented as a poster at this year's AACR Annual Meeting, GFH276 combined with EGFR monoclonal antibodies, chemotherapy, and other standard treatments demonstrated significant synergistic effects and superior tumor suppression, providing translational medicine rationale for this clinical study.
Dr. Wang Yu, Chief Medical Officer of Genfleet, stated: "Pan-RAS inhibitors have demonstrated the potential of innovative targeted therapy to rewrite survival outcomes for major indications in clinical studies of monotherapy and combination chemotherapy for pancreatic cancer and other solid tumors. Genfleet has successfully advanced multiple globally leading KRAS G12C/G12D inhibitor first-line combination therapy trials. Based on our deep experience in the RAS field, we will provide the most suitable treatment options for patients with different RAS mutations and push more outstanding innovative therapies to the frontline."
According to Frost & Sullivan data, approximately 30% of cancer patients worldwide harbor RAS mutations, with more than 6 million new RAS-mutant patients expected annually during 2025-2032, and nearly 90% of pancreatic cancer patients carry RAS mutations. Currently, multiple RAS therapies have been approved both domestically and internationally, and various molecular formats of investigational projects have entered mid-to-late stage clinical development, highlighting the growing potential and enormous market space of the RAS field. According to DelveInsight data, the ten-year compound annual growth rate (CAGR) for KRAS (the largest subtype of RAS mutations) inhibitors is 35%, and overseas research institutions have raised their peak sales forecasts for pan-RAS inhibitors from $230 million at the end of 2024 (GlobalData) to $8.3 billion by 2026 (Bloomberg).
Comments